What dose of 50% dextrose (D50W) should be administered in hyperkalemia?

D50W Dosing for Hyperkalemia

For hyperkalemia treatment in adults, administer D50W at 0.5-1.0 g/kg (equivalent to 1-2 mL/kg of 50% dextrose), given as an IV push along with 10 units of regular insulin. This translates to approximately 25-50 grams of dextrose (50-100 mL of D50W) for most adults 1, 2.

Dosing Algorithm

Standard Adult Dosing

• Dextrose dose: 0.5-1.0 g/kg (typically 25-50 g)
• D50W volume: 1-2 mL/kg (typically 50-100 mL)
• Insulin: 10 units regular insulin IV push
• Ratio: 1 unit insulin for every 4-5 grams of glucose 1

Critical Considerations for Dose Selection

Use the higher end (50 g dextrose) when:

• Pre-treatment glucose <110 mg/dL
• Patient is non-diabetic
• Patient has lower body weight
• Patient has acute kidney injury or end-stage renal disease 3, 4

Use the lower end (25 g dextrose) when:

• Pre-treatment glucose >150 mg/dL
• Patient has diabetes with adequate glucose control
• Risk of hyperglycemia is a concern

Administration Details

Route and Rate:

• Administer D50W as IV push over 3-5 minutes 2
• Give dextrose simultaneously with or immediately before insulin
• Critical warning: D50W is highly irritating to veins; ensure good IV access 1

Important caveat: The 2012 Critical Care Medicine guidelines note that rapid and repeated administration of 50% dextrose has been associated with cardiac arrest and hyperkalemia 5. Avoid bolusing multiple doses rapidly.

Hypoglycemia Prevention Strategy

The evidence reveals a significant problem: hypoglycemia occurs in 8.7-44% of patients treated for hyperkalemia with insulin and dextrose 6, 7, 8. This is a serious, often overlooked complication.

Enhanced Protocol to Reduce Hypoglycemia Risk

For patients with pre-treatment glucose ≤250 mg/dL AND impaired renal function (CrCl <30 mL/min or dialysis-dependent):

1. Initial bolus: 50 mL of D50W (25 g) IV push with insulin
2. Continuous infusion: Add 250 mL of D10W over 2 hours 6

This approach reduced hypoglycemia rates from 20% to 6% in a 2024 study 6.

Alternative Strategies

• Reduce insulin dose: Consider 5 units instead of 10 units (0.1 units/kg) 3
• Increase dextrose: Use 50 g instead of 25 g, particularly in non-diabetics 3, 4
• Prolonged dextrose infusion: Rather than single bolus 3

Monitoring Requirements

Mandatory glucose monitoring:

• Baseline glucose before treatment
• Hourly glucose checks for at least 4-6 hours post-insulin 3
• More frequent monitoring (every 15 minutes initially) may be needed during dextrose titration if using continuous infusion 9

High-risk patients requiring closer monitoring:

• Pre-treatment glucose <100 mg/dL
• Non-diabetic patients
• Female gender
• Acute kidney injury or ESRD
• Lower body weight 8, 3

Hypoglycemia typically occurs:

• Median onset: 2 hours post-treatment (range 1-2 hours) 7
• Can persist up to 2 hours after insulin administration 6
• 79% of hypoglycemic patients had AKI or ESRD 8

Pediatric Dosing

For children with hyperkalemia:

• Dextrose: 0.5-1.0 g/kg
• D50W volume: 1-2 mL/kg
• Insulin: 0.1 units/kg with 400 mg/kg glucose (maintaining 1:4 ratio) 1

Dilution recommendation: D50W is irritating to veins; dilution to 25% dextrose (D25W) is desirable in pediatric patients 1.

Common Pitfalls to Avoid

1. Insufficient dextrose: Using only 25 g when 50 g is indicated increases hypoglycemia risk 2-fold in vulnerable populations 4
2. Inadequate monitoring duration: Stopping glucose checks before 4-6 hours misses delayed hypoglycemia 3
3. Ignoring renal function: Patients with CrCl <30 mL/min have dramatically higher hypoglycemia risk 6, 8
4. Rapid repeated dosing: Multiple rapid D50W boluses can paradoxically worsen hyperkalemia and cause cardiac arrest 5
5. No continuous dextrose: Single bolus without follow-up infusion in high-risk patients 6

Expected Potassium Reduction

• Insulin/dextrose therapy shifts potassium intracellularly but does not eliminate total body potassium 10
• Effect begins within 30-60 minutes
• Duration of effect: 2-4 hours for beta-agonists; longer for insulin 10
• Must be combined with potassium elimination strategies (diuretics, dialysis, or potassium binders) for definitive management 10